Tnf receptor 2 related protein variant
CA 2453833 A1 · Owner: Warren, Bridget A. · Inventors: Lal, Preeti G.; Warren, Bridget A.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention provides a cDNA which encodes a TNFR2PV. It also provides for the use of the cDNA, fragments, complements and variants thereof and of the , encoded protein portions thereof and antibodies thereto for diagnosis and treatment of cancer and immune disorders particularly cancer of the prostate, ovary breast, colon, and brain, or an inflammatory disorder including , rheumatoid arthritis, asthma and ulcerative colitis. The invention additionally provides expression vectors and host cells for the production of the protein and a transgenic model system.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed July 24, 2002. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended July 24, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 24, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.